BUY Piramal Pharma — IDBI Capital, 21 Sept 2026

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))21 Sept 2026via IDBI Capital Research Calls Telegram

Entry₹211Stated

Target₹219

Stop loss₹207-1.90% risk

CMP₹210.125h ago

Active-0.42%+4.23%upside left 13d left

Follow IDBI Capital for new calls(28% target hit, 262 closed calls)Get alerts Watch PPLPHARMA for new buy/sell callsGet alerts See 1 other Swing call on PPLPHARMA See 181 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Sept, 9:26 pm IST

3 supporting1 neutral2 opposing

Supports the BUY call (3)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Sept · yesterday

Piramal Pharma earns ‘Leader’ ESG rating from independent assessor

NewsGoogle News·18 Sept · 4d ago

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·26 Aug · 4w ago

Neutral / worth noting (1)

Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility

NewsCnbc-Tv18·14 Sept · 1w ago

Weighs against the BUY call (2)

MACD below its signal line — bearish momentum

Technicals · macd·22 Sept · today

Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility

NewsCnbc-Tv18·15 Sept · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Piramal Pharma Limited — IDBI Capital

AI Assessment